Can Personalized Therapy Revolutionize COVID-19 Treatment Outcomes - Knowledge, Attitude & Practice Survey
Personalized Drug Therapy
Background: COVID-19 shows variability depending on ethnicity and environmental factors therefore one type of drug may not be effective in all the populations. Personalized medicine refers to tailoring the treatment in accordance with individual patients. In the current COVID-19 crisis can this therapy change the course of research and treatment? A study was conducted to investigate the number of physicians with knowledge about personalized medicine and if it was being applied into routine practice, to direct the use of P drug for COVID-19 treatment.
Methods: A cross-sectional survey was carried out at Khyber Girl’s Medical College Hayatabad. Respondents included 100 doctors of various specialties who were interviewed regarding the knowledge of personalized therapy for various diseases and their impact on treatment outcomes. They were investigated if according to their experience of tailoring, it could bring about better treatment outcomes for COVID-19.
Results: Out of the total 100 89 (89%) doctors were routinely prescribing tailored treatment and believed that the COVID-19 research should be modified through personalization and genetics.
Conclusion: Personalized therapy is more targeted hence brings about therapeutic benefits and it would ensure better therapeutic outcomes in COVID-19 cases.
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020 Mar 17;323(11):1061-9. DOI: 10.1001/jama.2020.1585
3. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. MedRxiv. 2020 Jan 1. DOI: 10.1101/2020.02.10.20021675
4. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. j. 2020 Feb 28. DOI: 10.1097/CM9.0000000000000775.
5. Yancy CW. COVID-19 and African Americans. Jama. 2020 Apr 15. DOI:10.1001/jama.2020.6548
6. Shi S, Qin M, Shen B. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol. Published online March 25, 2020. DOI: 10.1001/jamacardio.2020. 0950
7. Pareek M, Bangash MN, Pareek N, Pan D, Sze S, Minhas JS, et al. Ethnicity and COVID-19: an urgent public health research priority. The Lancet. 2020 Apr 21. DOI: 10.1016/S0140-6736(20)30922-3
8. Laurencin CT, McClinton A. The COVID-19 pandemic: a call to action to identify and address racial and ethnic disparities. J. Racial Ethn. Health Disparities. 2020 Apr 18:1-5. DOI: 10.1007/s40615-020-00756-0
9. Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015 Apr;520(7549):609-611. URL: https://www.nature.com/news/personalized-medicine-time-for-one-person-trials-1.17411
10. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI insight. 2018 Aug 9;3(15). DOI: 10.1172/jci.insight.120858
11. Sharma A, Buschmann MM, Gilbert JA. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response. Cpt. 2019 Apr 2.
12. Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. Obstet. Gynecol. Surv. 2015 Oct 1;70(10):612-4. DOI: 10.1097/01.ogx.0000472121.21647.38
13. Ashley EA. Towards precision medicine. Nat. Rev. Genet. 2016 Sep;17(9):507. DOI: 10.1038/nrg.2016.86
14. Khoury MJ, Galea S. Will precision medicine improve population health? Jama. 2016 Oct 4;316(13):1357-8. DOI: 10.1001/jama.2016.12260
15. Everett JR. Pharmacometabonomics in humans: a new tool for personalized medicine. Pgs. 2015 May;16(7):737-54. DOI: 10.2217/pgs.15.20
16. Joyner MJ, Paneth N. Seven questions for personalized medicine. Jama. 2015 Sep 8;314(10):999-1000. DOI: 10.1001/jama.2015.7725
17. Alharbi AA, Shaqran TM, Eltobgy AA et al. Physicians’ Perspective on Diabetes Mellitus Management within the Context of Personalized Medicine Era in Tabuk Governorate, Saudi Arabia. OAMJMS. 2019 May 31;7(10):1706. DOI: 10.3889/oamjms.2019.322
18. Kaphingst KA, Goodman MS. Importance of race and ethnicity in individuals’ use of and responses to genomic information. Pme. 2016 ;1-4. DOI: 10.2217/pme.15.39
19. Owusu Obeng A, Fei K, Levy K, Elsey A et al. Physician-reported benefits and barriers to clinical implementation of genomic medicine: a multi-site Ignite-network survey. jpm. 2018 Sep;8(3):24. DOI: 10.3390/jpm8030024
20. Chow-White P, Ha D, Laskin J. Knowledge, attitudes, and values among physicians working with clinical genomics: a survey of medical oncologists. Hum. Resour. Health. 2017 Dec;15(1):42. DOI: 10.1186/s12960-017-0218-z
21. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Pnas. 2020 Apr 28;117(17):9490-6. DOI: 10.1073/pnas.2004168117
22. Zhao H, Harris RJ, Ellis J, Pebody RG. Ethnicity, deprivation and mortality due to 2009 pandemic influenza A (H1N1) in England during the 2009/2010 pandemic and the first post-pandemic season. Epidemiol Infect. 2015 Dec;143(16):3375-83. DOI: 10.1017/S0950268815000576
Copyright (c) 2020 Manzoor Khan, Sarwat Jahan, Naila Abrar, Laila Saleem, Rabia Mazhar, Abid Hussain
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.